- Home
- VHC vs CUE Comparison
VHC vs CUE Comparison
Compare VHC & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VHC | CUE |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 49.6M |
| IPO Year | 1999 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VHC | CUE |
|---|---|---|
| Price | $18.71 | $0.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 16.2K | ★ 249.2K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $106,000.00 | ★ $7,100,000.00 |
| Revenue This Year | N/A | $36.58 |
| Revenue Next Year | N/A | $32.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2020.00 | N/A |
| 52 Week Low | $3.68 | $0.47 |
| 52 Week High | $29.00 | $1.75 |
Technical Indicators
Market Signals| Indicator | VHC | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 42.34 | 29.93 |
| Support Level | $18.21 | $0.47 |
| Resistance Level | $22.27 | $0.51 |
| Average True Range (ATR) | 1.99 | 0.05 |
| MACD | -0.27 | -0.01 |
| Stochastic Oscillator | 10.20 | 10.78 |
Price Performance
Historical ComparisonAbout VHC VirnetX Holding Corp
VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.